Obstructive sleep apnoea (OSA) is a common sleep disorder in which breathing repeatedly slows or stops during sleep. When throat muscles relax, the airway can collapse or become blocked, causing drops in oxygen levels and repeated sleep interruptions, often without the person fully waking up. Snoring often occurs because the narrowed airway vibrates during breathing, and while snoring alone isn't dangerous, it can be a sign of OSA when combined with choking, gasping, or noticeable pauses in breathing.
OSA is one of Australia's most widespread sleep disorders, particularly among adults, affecting 20% of adults. Many people with OSA remain undiagnosed, meaning the true number of Australians living with the condition is likely even higher than current estimates suggest. Untreated OSA can increase the risk of high blood pressure, heart attack, stroke, diabetes, and depression, and contributes to excessive daytime sleepiness, poor concentration, and higher rates of accidents. Despite its prevalence, many people struggle with or cannot tolerate standard treatments like CPAP, leaving a significant gap in care for those living with both obesity and moderate to severe OSA.
This trial is evaluating a once-weekly investigational medicine that may help address both weight and OSA symptoms, exploring a potential new approach for people who haven't found adequate relief with existing options.
